Leyi Wang

Leyi Wang

Auto-generated profile, based on publicly available information

Leyi Wang

Aerospace Center Hospital

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2022 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
XQXiaoying Qiao
Xiaoying Qiao
JBJaroslaw Bilinski
Jaroslaw Bilinski
LWLeyi Wang
Leyi Wang
TYTianyu Yang
Tianyu Yang
RLRongmu Luo
Rongmu Luo
GYGuibin Yang
Guibin Yang

15 August 2023
Verified
Preprint
Open access
PDF file
LWLeyi Wang
Leyi Wang
TLTonghao Lei
Tonghao Lei
WZWenchang Zhang
Wenchang Zhang
CHChangjian He
Changjian He
WSWence Shi
Wence Shi
LDLigang Ding
Ligang Ding
Aim: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) have been reported to manifest controversial relationships with cancer, and recent focus concerning the tumorigenic effect of ACEIs mainly falls on lung cancer. We compared ACEIs with ARBs for their impact on the risk and prognosis of lung cancer and non-lung cancers, respectively. Methods: A meta-analysis was performed to explore the impact of ACEIs on the risk of lung cancer and non-lung cancers, while a systematic review was performed to further analyze ACEIs’ influence on the prognosis of lung cancer. Terms concerning ACEIs and cancer were searched, and 10 cohort studies were included for risk analysis, while 5 cohort studies were included for analyzing the prognosis of lung cancer. Results: Initial pooled result revealed that ACEIs prescription is associated with an observed increase on the risk of lung cancer (RR 1.28, 95% CI 1.02-1.61), colorectal cancer (RR 1.46, 95% CI 1.13-1.87) and hepatic cancer (RR 2.00, 95% CI 1.01-3.94) when compared with ARBs, but further sensitivity analyses suggested the results unsolid, thus neither the development of lung cancer nor non-lung cancers could be proved associated with ACEIs prescription. However, systematic review suggested that ACEIs prescription is associated with an improved lung cancer prognosis. Conclusion: There has been no adequate evidence to demonstrate that ACEIs are associated with a higher incidence of lung cancer or non-lung cancers, but an improved prognosis of lung cancer was observed in patients taking ACEIs. Large-scale RCTs are needed and underlying mechanisms need further exploration.